Take Solutions LimitedTAKECorporate

Healthcare Research, Analytics & Technology Latest results: Jun 2026 14 quarters of data
₹12.58
MCap ₹184 Cr · P/E 31.4
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹12 Cr
Sales · Jun 2026
₹-0 Cr
Operating Profit · Jun 2026
+82.2% YoY
-3.0%
OPM % · Jun 2026
₹1 Cr
Net Profit · Jun 2026
+144.6% YoY
₹0.07
EPS · Jun 2026
+146.7% YoY

📝 Take Solutions Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Take Solutions Limited reported revenue of ₹12 crore for the quarter ended June 2026 (Q1 FY27).

The company swung to a net profit of ₹1 crore from a net loss of ₹2 crore a year earlier. Earnings per share (EPS) came in at ₹0.07.

Operating profit stood at ₹-0 crore — an operating margin (OPM) of -3.0%.

Full year and trailing twelve months

For the full year FY26, Take Solutions Limited posted revenue of ₹-0 crore, a decline of 104.4% over FY25, with a net profit of ₹3 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹12 crore with a net profit of ₹6 crore.

Valuation snapshot

At the current price of ₹12.58, TAKE has a market capitalisation of ₹184 crore and a trailing P/E of about 31.4.

Within the Healthcare Research, Analytics & Technology industry, it is the 6th-largest of the 10 companies we track by market value.

Shareholding pattern

As of Jun 2026, foreign institutional investors (FIIs) 0.21%, public shareholders 99.79% of Take Solutions Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹184 Cr
Current Price ?
₹12.6
P/E ?
31.44below ind
Industry P/E ?
35.60
P/B ?
6.46
P/S ?
15.42
P/FCF ?
-296.70
Enterprise Value ?
₹184 Cr
EV/EBITDA ?
-103.18
PEG ?
N/A
Earnings Yield ?
-1.0%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹12 Cr
OPM ?
-14.9%
Profit after tax (TTM) ?
₹6 Cr
EPS (TTM) ?
₹0.40
ROCE ?
11.7%
ROE ?
20.5%
ROA ?
19.5%
Growth
Sales — latest qtr ?
₹12 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
144.6%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
-32%
Profit growth (5y) ?
20%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
-11.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
Pledged percentage ?
N/A
Market
Return 3 months ?
-34.0%
Return 6 months ?
-74.4%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 15500010000-00012 — —
Operating Profit 31-1-2-80-1-1-1-2-0-0-1-0 +82.2% +54.6%
Other Income 7001-12-48-27260-0151 +13178.0% -74.4%
Interest 00000000000000 -99.5% —
Depreciation 00000000000000 — —
Profit Before Tax 40-1-1-201-48-2815-2-0141 +144.8% -77.9%
Net Profit 4-0-1-5-201-48-2815-2-1141 +144.6% -77.9%
EPS 0.280.00-0.07-0.31-13.62-3.24-1.860.060.32-0.15-0.040.080.300.07 +146.7% -76.7%
OPM % 18.3% 18.6% — — — 32.2% — — — — 712.5% — — -3.0% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1 Cr ₹-0 Cr ₹12 Cr -104.4%
Operating Profit ₹-2 Cr ₹-3 Cr ₹-2 Cr -66.4%
OPM % -230.00% 8,610.50% -14.95% +3843.7%
NPM % -7,747.78% -6,780.00% 49.04% +12.5%
Other Income ₹-67 Cr ₹7 Cr ₹8 Cr +109.9%
Depreciation ₹0 Cr ₹0 Cr ₹0 Cr -90.0%
Interest ₹1 Cr ₹0 Cr ₹0 Cr -59.9%
EBIT ₹-2 Cr ₹-3 Cr ₹-2 Cr -63.4%
PBT ₹-70 Cr ₹3 Cr ₹6 Cr +104.1%
Tax — ₹0 Cr ₹0 Cr —
Net Profit ₹-70 Cr ₹3 Cr ₹6 Cr +103.9%
EPS ₹-4.72 ₹0.19 ₹0.41 +104.0%
Material Cost — ₹0 Cr ₹12 Cr —
Employee Cost — ₹0 Cr ₹0 Cr —
Extraordinary Items — — ₹0 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14.7914.7914.7914.79 +0.0%
Reserves 287.9880.6210.9713.69 +24.8%
Borrowings 1.820.000.000.00 —
Other Liabilities 14.1123.775.911.57 -73.4%
Total Liabilities 318.70119.1831.6730.05 -5.1%
Fixed Assets 2.120.110.010.00 -100.0%
CWIP 0.000.000.000.00 —
Investments 242.56101.870.000.25 —
Other Assets 74.0217.2031.6629.80 -5.9%
Total Assets 318.70119.1831.6730.05 -5.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 26.89-4.48-19.51-0.62 +96.8%
Cash from Investing Activity -22.37-1.0222.21-2.00 -109.0%
Cash from Financing Activity -0.84-0.23-0.04-0.29 -625.0%
Net Cash Flow 3.69-5.732.66-2.91 -209.4%
Free Cash Flow 26.89-4.49-19.51-0.62 +96.8%
CFO/OP 1,095%40%966%13% -98.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 0.000.000.00— —
Cash Conversion Cycle 0.000.000.00— —
Working Capital Days 241.86-1,163.025,406.06— —
ROCE % 3.57%-4.68%17.96%11.65% -35.1%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 53.34%5.19%0.00%0.00%— —
FIIs 0.00%0.00%0.56%0.28%0.21% -25.0%
DIIs 0.00%0.00%0.00%0.00%— —
Public 46.65%94.81%99.44%99.73%99.79% +0.1%
No. of Shareholders 75,14174,41070,32464,69963,213 -2.3%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Take Solutions Limited's revenue in Q1 FY27?
Take Solutions Limited reported revenue of ₹12 crore for the quarter ended June 2026 (Q1 FY27).
What was Take Solutions Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹1 crore from a net loss of ₹2 crore a year earlier. Earnings per share (EPS) came in at ₹0.07.
What is TAKE's market capitalisation and P/E ratio?
At the current price of ₹12.58, TAKE has a market capitalisation of ₹184 crore and a trailing P/E of about 31.4.
Who owns Take Solutions Limited? (shareholding pattern)
As of Jun 2026, foreign institutional investors (FIIs) 0.21%, public shareholders 99.79% of Take Solutions Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI